Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells

Yizi Cong,Yuxin Cui,Shiguang Zhu,Jianqiao Cao,Haidong Zou,Tracey A.Martin,Guangdong Qiao,Wenguo Jiang,Zhigang Yu
DOI: https://doi.org/10.21203/rs.2.22315/v1
2020-01-01
Chinese Journal of Cancer Research
Abstract:Objective: Although T-cell immunoglobulin and mucin-domain containing molecule-3(Tim-3) has been recognized as a promising target for cancer immunotherapy, its exact role in breast cancer has not been fully elucidated.Methods: Tim-3 gene expression in breast cancer and its prognostic significance were analyzed. Associated mechanisms were then explored in vitro by establishing Tim-3-overexpressing breast cancer cells.Results: In a pooled analysis of The Cancer Genome Atlas(TCGA) database, Tim-3 gene expression levels were significantly higher(P<0.001) in breast cancer tissue, compared with normal tissues. Tim-3 was a prognosis indicator in breast cancer patients [relapse-free survival(RFS), P=0.004; overall survival(OS), P=0.099]. Tim-3 overexpression in Tim-3 low breast cancer cells promoted aggressiveness of breast cancer cells, as evidenced by enhanced proliferation, migration, invasion, tight junction deterioration and tumor-associated tubal formation.Tim-3 also enhanced cellular resistance to paclitaxel. Furthermore, Tim-3 exerted its function by activating the NF-κB/STAT3 signalling pathway and by regulating gene expression [cyclin D1(CCND1), C-Myc, matrix metalloproteinase-1(MMP1), TWIST, vascular endothelial growth factor(VEGF) upregulation, concomitant with Ecadherin downregulation). Lastly, Tim-3 downregulated tight junction-associated molecules zona occludens(ZO)-2, ZO-1 and occludin, which may further facilitate tumor progression.Conclusions: Tim-3 plays an oncogenic role in breast cancer and may represent a potential target for antitumor therapy.
What problem does this paper attempt to address?